帕罗西汀合并丙戊酸镁缓释片治疗难治性抑郁症的临床研究

目的探讨帕罗西汀合并丙戊酸镁缓释片治疗难治性抑郁症的临床疗效。方法将60例难治性抑郁症患者随机分为帕罗西汀合并丙戊酸镁缓释片组和单用帕罗西汀组，每组各30例，疗程8周，观察比较治疗4周和8周后汉密尔顿抑郁量表评分情况及临床疗效。结果研究组治疗8周后有效率76．7％，对照组有效率50％，差异有统计学意（P〈0．05）。治疗4周末，8周末研究组汉密尔顿抑郁量表均较对照组下降更显著（P〈0．01）。两组副反应差异无统计学意义（P〉0．05）。结论帕罗西汀合并丙戊酸镁缓释片治疗难治性抑郁症疗效更显著，优于单用帕罗西汀治疗。

Paroxetine combined with magnesium valproate sustained release tablets for refractory depression

Objective To explore the clinical efficacy of paroxetine combined with magnesium valproate sustained release tablets in the treatment of refractory depression. Methods 60 patients with refractory depression were randomly divided into two groups, 30 for each group. The study group received paroxetine combined with magnesium valproate sustained release tablets, while the control group received paroxetine alone for 8 weeks. The scores on the Hamilton Depression Scale and the clinical efficacy were observed and then compared between the two groups 4 and 8 weeks after treatment. Results 8 weeks after treatment, the effectiveness rate was 76.7% in the study group and 50% in the control group, with significant differences （P〈0.01）. The scores on the Hamilton Depression Scale decreased more significantly in the study group than in the control group at the end of 4 and 8 weeks （P〈0.01）. There were no significant differences in side effccts between the two groups （P〉0.05）. Conclusions Paroxetine combined with magnesium valproate sustained release tablets is more effective than paroxetine alone in the treatment of refractory depression.